Anti-interleukin-17A biologics for the long-term treatment of bullous pemphigoid: A prospective, cohort study.

Bakirtzi, K; Sotiriou, E; Papadimitriou, I; Vakirlis, E; Delli, F S; Ioannides, D

Bakirtzi, K; Sotiriou, E; Papadimitriou, I; Vakirlis, E; Delli, F S; Ioannides, D.

Affiliation

Bakirtzi K; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Sotiriou E; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Papadimitriou I; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Vakirlis E; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Delli FS; State Dermatology Department, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece.
Ioannides D; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

J Eur Acad Dermatol Venereol ; 37(6): e749-e751, 2023 06.

Article in En | MEDLINE | ID: mdl-36688248

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biological Products / Pemphigoid, Bullous Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2023 Document type: Article Affiliation country: Grecia Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google